Myasthenia Gravis (MG) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026
Myasthenia Gravis (MG) Emerging Therapy and TPP Insights Thelansis’s “Myasthenia Gravis (MG) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Myasthenia Gravis (MG) Overview Myasthenia gravis is an autoimmune disorder in which the immune system produces antibodies that disrupt communication between nerves and muscles, causing fluctuating weakness that can affect the eyes, face, throat, limbs, and, in severe cases, breathing. For decades, treatment relied heavily on broad immune suppression through corticosteroids and related agents, which controlled symptoms but carried substantial long-term side effects. That has changed with two new classes of precision therapy targeting the specific immune mechanisms driving the disease rather than su...